Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 6,517 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Completed Phase 2 Interventional Results available

Effect of Inhaled Albuterol in Pulmonary Hypertension

NCT03270332
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Albuterol, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 26, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional

Impact of Hospital to Home: Optimizing Preterm Infant Environment for Surgical Neonates and Their Parents (H-HOPE)

NCT07372898
View directory record Official record
Conditions
Oral Feeding Outcomes, Neurodevelopment Outcome
Interventions
H-HOPE
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Week to 8 Weeks
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 26, 2026, 5:37 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

NCT06948214
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
LUM-201, Matched Placebo (Capsules)
Drug · Other
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Madera, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

NCT01125904
View directory record Official record
Conditions
Healthy
Interventions
crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2010 · Synced Oct 26, 2026, 5:37 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood

NCT00823433
View directory record Official record
Conditions
Group B Streptococcus
Interventions
oral penicillin V
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

NCT01735630
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ELND005, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

NCT04346628
View directory record Official record
Conditions
Sars-CoV2, COVID-19
Interventions
Favipiravir, Placebo, Standard of care treatment
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

IBUPAP Study for Pain Management in Children

NCT03088800
View directory record Official record
Conditions
Pain Management
Interventions
Ibuprofen, APAP
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
3 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 26, 2026, 5:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT07667400
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
SX-682, DTX
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

NCT01432600
View directory record Official record
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Early Phase 1 Interventional Results available

Transgender Estradiol

NCT04036500
View directory record Official record
Conditions
Transgender Persons
Interventions
Estradiol
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 26, 2026, 5:37 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Pilot Randomized Control Trial Comparing Oral Ketamine and Oral Oxycodone for Pain Control in Emergency Department Patients

NCT07670507
View directory record Official record
Conditions
Pain Management
Interventions
oral ketamine, oxycodone
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Patiromer With or Without Food for the Treatment of Hyperkalemia

NCT02694744
View directory record Official record
Conditions
Hyperkalemia
Interventions
patiromer
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
29
States / cities
Fountain Valley, California • Huntington Beach, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 26, 2026, 5:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Microbiome and Pancreatic Cancer

NCT03302637
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
16S rRNA gene sequencing assay
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 74 Years
Enrollment
732 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Rinse, Placebo, C16G2 Gel
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Not applicable Interventional

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis

NCT00002134
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Roche Global Development
Other
Eligibility
13 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Megace in HIV-Infected Women

NCT00002345
View directory record Official record
Conditions
Anorexia, Cachexia, HIV Infections
Interventions
Megestrol acetate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 26, 2026, 5:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012
View directory record Official record
Conditions
Healthy Elderly
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 26, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

NCT04628481
View directory record Official record
Conditions
Recent Onset type1 Diabetes
Interventions
Ladarixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
14 Years to 45 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

NCT02210000
View directory record Official record
Conditions
Gastroparesis
Interventions
Placebo, Camicinal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Chandler, Arizona • Long Beach, California • Northridge, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00121264
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sorafenib tosylate, tanespimycin, laboratory biomarker analysis, pharmacological study, magnetic resonance imaging
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AME Study of [14C]-YH4808 in Healthy Male Subjects

NCT01825707
View directory record Official record
Conditions
Healthy
Interventions
[14C]-YH4808 200 mg
Drug
Lead sponsor
Yuhan Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 26, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

NCT02390492
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Period 1 treatment, Period 2 treatment
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 5:37 PM EDT